Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Other Operating Expenses: 2012-2025

Historic Other Operating Expenses for Ptc Therapeutics (PTCT) over the last 9 years, with Sep 2025 value amounting to $23.8 million.

  • Ptc Therapeutics' Other Operating Expenses rose 3498.14% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.3 million, marking a year-over-year increase of 1778.07%. This contributed to the annual value of $4.5 million for FY2024, which is 96.50% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Other Operating Expenses stood at $23.8 million, which was up 52.68% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Other Operating Expenses registered a high of $128.9 million during Q2 2023, and its lowest value of -$10.8 million during Q3 2021.
  • For the 3-year period, Ptc Therapeutics' Other Operating Expenses averaged around $15.7 million, with its median value being $800,000 (2025).
  • Within the past 5 years, the most significant YoY rise in Ptc Therapeutics' Other Operating Expenses was 11,800.00% (2022), while the steepest drop was 152.07% (2022).
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Other Operating Expenses stood at $12.1 million in 2021, then crashed by 152.07% to -$6.3 million in 2022, then spiked by 142.86% to $2.7 million in 2023, then skyrocketed by 276.85% to $10.2 million in 2024, then surged by 3,498.14% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q3 2025, $15.6 million for Q2 2025, and $800,000 during Q1 2025.